Bullish (but half-baked) EGRX write-up from TheStreet.com: http://www.thestreet.com/story/13380098/2/eagle-a-bright-spot-in-pharma-landscape.html The write-up doesn’t even mention EGRX’s programs for Docetaxel, Angiomax, and Alimta!